Multiple Sclerosis

  • Ludo J. VanopdenboschEmail author
  • David J. Oliver


Despite the successes of newer disease modifying therapies for multiple sclerosis, patients and families continue to have enormous palliative care needs. These needs are driven by the long and uncertain trajectory of the heterogeneous physical, psychological, and social effects of this disease. Comprehensive and vigilant multi-disciplinary care is essential to optimize function and quality of life, through treatments and social support systems. Primary palliative care is an essential component to all teams providing care to patients with multiple sclerosis, and they should have ready access to specialist palliative care if needed. Data suggests early palliative care might be useful in MS but more research and education are needed to better define the timing and role of a palliative care approach to patients and families with multiple sclerosis.


Multiple sclerosis Palliative care Disease modifying agents End of life Spasticity Depression 


  1. 1.
    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple sclerosis. NEJM. 2000;343:938–52.CrossRefGoogle Scholar
  2. 2.
    Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. NEJM. 2006;354:942–55.CrossRefGoogle Scholar
  3. 3.
    Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. NEJM. 2016;376:221–34.CrossRefGoogle Scholar
  4. 4.
    Oliver DJ, Borasio GD, Caraceni A, et al. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol. 2016;23:30–8.CrossRefGoogle Scholar
  5. 5.
    Ontanada D, Fox RJ. Progressive multiple sclerosis. Curr Opin Neurol. 2015;28:237–43.CrossRefGoogle Scholar
  6. 6.
    Ontanada D, Thompson A, Fox R, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair and restoration of function. Lancet. 2017;389:1357–66.CrossRefGoogle Scholar
  7. 7.
    Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.CrossRefGoogle Scholar
  8. 8.
    Trojano M, Tintore M, Montalban X, et al. Treatment decisions in multiple sclerosis – insights from real-world observational studies. Nat Rev Neurol. 2017;13:105–18.CrossRefGoogle Scholar
  9. 9.
    Giovannoni G, Tomic D, Bright JR, Havrdova E. “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23:1179–87.CrossRefGoogle Scholar
  10. 10.
    Strupp J, Hartwig A, Golla H, et al. Feeling severely affected by multiple sclerosis: what does this mean? Palliat Med. 2012;26:1001–10.CrossRefGoogle Scholar
  11. 11.
    Aridegbe T, Kandler R, Walters SJ, et al. The natural history of motor neuron disease: assessing the impact of specialist care. Amytroph Lat Scler. 2013;14:13–9.Google Scholar
  12. 12.
    Bede P, O’Brannagain D, Hardiman O. Development of an interactive software for evidence-based symptomatic management of motor neuron disease with specific trigger points to specialist palliative care intervention. Eur J Neurol. 2010;17(S3):291.Google Scholar
  13. 13.
    Turner-Stokes L, Sykes N, Silber E. Long-term neurological conditions: management at the interface between neurology, rehabilitation and palliative care. Clin Med. 2008;8(2):186–91.CrossRefGoogle Scholar
  14. 14.
    Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017:1–5. Scholar
  15. 15.
    Cutter GR, Zimmerman J, Salter AR, et al. Causes of death among persons with multiple sclerosis. Mult Scler Relat Disord. 2015;4:484–90.CrossRefGoogle Scholar
  16. 16.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907–11.CrossRefGoogle Scholar
  17. 17.
    Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133:1900–13.CrossRefGoogle Scholar
  18. 18.
    Talmage GD, Coppes OJM, Javed A, Bernard J. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: a prospective, non-randomized pilot study. PLoS One. 2017;12:e0173299.CrossRefGoogle Scholar
  19. 19.
    National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. Clinical Guideline 186. 2014. NICE (Accessed 27 Jun 2017).
  20. 20.
    Simmons RD. Life issues in multiple sclerosis. Nat Rev Neurol. 2010;6:603–10.CrossRefGoogle Scholar
  21. 21.
    De Sa JCC, Airas L, Bartholome E, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011;4:139–68.CrossRefGoogle Scholar
  22. 22.
    Hirsh AT, Turner AP, Ehde DM, Haselkorn JK. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil. 2009;90:646–51.CrossRefGoogle Scholar
  23. 23.
    Putzki N, Pfriem A, Limmroth V, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol. 2009;16:262–7.CrossRefGoogle Scholar
  24. 24.
    Chohan H, Greenfield A, Yadav V, Graves J. Use of cannabinoids for spasticity and pain management in MS. Curr Treatm Opt Neurol. 2016;18:1–14.CrossRefGoogle Scholar
  25. 25.
    Kabus C, Hecht M, Japp G, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol. 2006;253(S1):26–8.CrossRefGoogle Scholar
  26. 26.
    Sammaraiee Y, Yardley M, Keenan L, Buchanan K, Stevenson V, Farrell R. Long-term efficacy of intrathecal baclofen to manage severe spasticity in MS patients. Mult Scler. 2016;22(S3):684–5.Google Scholar
  27. 27.
    Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. 2014;2014:798285. Epub 2014 May 14.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology. 2010;7513:1141–9.CrossRefGoogle Scholar
  29. 29.
    Yang TT, Wang L, Deng XY, Yu G. Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017;380:256–61.CrossRefGoogle Scholar
  30. 30.
    Cameron M. Effects of methylphenidate on mobility, cognition and fatigue in multiple sclerosis: a pilot randomized controlled trial. Neurology. 2017;88(16S):P3.341.Google Scholar
  31. 31.
    Oliveria SF, Rodriguez RL, Bowers D, et al. Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial. Lancet Neurol. 2017;16:691–700.CrossRefGoogle Scholar
  32. 32.
    Sarkar P, Cole A, Scolding NJ, Rice CM. Percutaneous endoscopic gastrostomy tube insertion in neurodegenerative disease: a retrospective study and literature review. Clin Endosc. 2017;50:270–8.CrossRefGoogle Scholar
  33. 33.
    Pereira CMA, Castiglione M, Kasawara KT. Effects of physiotherapy treatment for urinary incontinence in patient with multiple sclerosis. J Phys Ther Sci. 2017;29:1259–63.CrossRefGoogle Scholar
  34. 34.
    Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318:1592–604.CrossRefGoogle Scholar
  35. 35.
    Macleod AD, Formaglio F. Demyelinating disease. In: Voltz R, Bernat JL, Borasio GD, Maddocks I, Oliver D, Portenoy RK, editors. Palliative care in neurology. Oxford: Oxford University Press; 2004. p. 33–4.Google Scholar
  36. 36.
    Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012;73:411–7.CrossRefGoogle Scholar
  37. 37.
    Federal Control and Evaluation Committee for Euthanasia. Seventh report to Parliamant. January 1 2014 to December 31 2015. (In Dutch). Available online: Accessed 25 Jun 2017.
  38. 38.
    End of life care in long term neurological conditions: a framework for implementation. National End of Life Care Programme 2010. Accessed 25 June 2017.
  39. 39.
    Hussain J, Adams D, Allgar V, Campbell C. Triggers in advanced neurological conditions: prediction and management of the terminal phase. BMJ Supp Palliat Care. 2014;4:30–7.CrossRefGoogle Scholar
  40. 40.
    GSF, G.-S.-F. Proactive Identification Guidance 2016. Available from: Accessed 27 Feb 2017.
  41. 41.
    Topcu G, Buchanan H, Aubeeluck A, Garip G. Caregiving in multiple sclerosis and quality of life: a meta-synthesis of qualitative research. Psychol Health. 2016;31:693–710.CrossRefGoogle Scholar
  42. 42.
    Buchanan RJ, Radin D, Huang C. Caregiver burden among informal caregivers assisting people with multiple sclerosis. Int J MS Care. 2011;13:76–83.CrossRefGoogle Scholar
  43. 43.
    Buchanan RJ, Radin D, Chakravorty BJ, Tyry T. Informal care giving to more disabled people with multiple sclerosis. Disabil Rehabil. 2009;31:1244–56.CrossRefGoogle Scholar
  44. 44.
    Borreani C, Bianchi E, Cilia S, et al. Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. PLoS One. 2014;9:e109679.CrossRefGoogle Scholar
  45. 45.
    Higginson IJ, McCrone P, Hart SR, et al. Is short-term palliative care cost-effective in Multiple sclerosis? A randomized phase II trial. J Pain Symptom Manag. 2009;38:816–26.CrossRefGoogle Scholar
  46. 46.
    Edmonds P, Hart S, Gao W, et al. Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service. Mult Scler. 2010;16:627–36.CrossRefGoogle Scholar
  47. 47.
    Solari A, Giordano G, Patti F, et al. Randomised controlled trial of a home based palliative approach for people with severe muliple sclerosis. Mult Scler. 2017.
  48. 48.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyAZ Sint Jan Brugge OostendeBruggeBelgium
  2. 2.Tizard CentreUniversity of KentCanterbury, KentUK

Personalised recommendations